Diffuse Large B-Cell LymphomaPhase 3NCT01287741
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
A Phase 3 study testing Rituximab, Obinutuzumab and Cyclophosphamide in people with Diffuse Large B-Cell Lymphoma, run by Hoffmann-La Roche at 235 sites in 29 countries.
Trial summary
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diffuse Large B-Cell Lymphoma
- What is being tested?
- Rituximab, Obinutuzumab and Cyclophosphamide
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,418 participants
- Where
- 235 sitesin 29 countries
- Study dates
- 26 Jul 2011to 31 Jan 2018
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Previously untreated CD20-positive DLBCL
- At least 1 bi-dimensionally measurable lesion (greater than [>]1.5 centimeters [cm] in its largest dimension on the computed tomography [CT] scan)
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- Adequate hematological function
- Low-intermediate, high-intermediate or high-risk International Prognostic Index (IPI) score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky disease, defined as one lesion greater than equal to (>/=) 7.5 cm)
- Left ventricular ejection fraction (LVEF) >/=50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram
Who cannot join
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products or to any component of CHOP or obinutuzumab
- Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
- Participants with transformed lymphoma and participants with follicular lymphoma IIIB
- Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation
- Prior treatment with cytotoxic drugs or rituximab for another condition (for example, rheumatoid arthritis) or prior use of an anti-CD20 antibody
- Prior use of any monoclonal antibody within 3 months of the start of Cycle 1
- Corticosteroid use of >30 milligrams per day (mg/day) of prednisone or equivalent, for purposes other than lymphoma symptom control
- Primary central nervous system (CNS) lymphoma and secondary CNS involvement by lymphoma, mantle-cell lymphoma (MCL), or histologic evidence of transformation to a Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, plasmablastic lymphoma, and primary cutaneous DLBCL
Trial locations and contacts
235 sites in 29 countries.
235 sites in 29 countries
United States36 sites
New York Oncology Hematology, P.C.
Albany, New York, 12206
Texas Oncology, Pa - Amarillo
Amarillo, Texas, 79106
Rocky Mountain Cancer Center - Aurora
Aurora, Colorado, 80012
University of Alabama at Birmingham
Birmingham, Alabama, 35294-3300
Ironwood Cancer TX & Rsch Ctrs
Chandler, Arizona, 85224
Medical University of SC (MUSC)
Charleston, South Carolina, 29425
Mecklenburg Medical Group Charlotte
Charlotte, North Carolina, 28204
Chattanooga Oncology and Hematology Associates, PC
Chattanooga, Tennessee, 37404
South Carolina Oncology Associates - SCRI
Columbia, South Carolina, 29210
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California, 92008
cCare
Encinitas, California, 92024
Florida Cancer Specialists; Department of Oncology
Fort Myers, Florida, 33901-8101
Texas Oncology-Fort Worth 12th Ave
Fort Worth, Texas, 76104
Illinois Cancer Care, P.C. - Galesburg
Galesburg, Illinois, 61401
MD Anderson Cancer Center Department of Lymphoma & Myeloma
Houston, Texas, 77030
Joliet Oncology-Hematology; Associates, Ltd.
Joliet, Illinois, 60435
UCLA - School of Medicine; Division of Hematology/Oncology
Los Angeles, California, 90095-6984
Central Georgia Cancer Care PC
Macon, Georgia, 31201
Signal Point Clinical; Research Center, LLC
Middletown, Ohio, 45042
Tennessee Onc., PLLC - SCRI
Nashville, Tennessee, 37203
Cancer Care Centers of South Texas-HOAST - San Antonio
New Braunfels, Texas, 78130
Cancer Care & Hematology; Specialists of Chicagoland
Niles, Illinois, 60714
Mercy Oncology / Hematology Center; Oncology
Portland, Maine, 04102
Virginia Cancer Institute
Richmond, Virginia, 23226
Blue Ridge Cancer Care
Roanoke, Virginia, 24014
Park Nicollet Clin-Cancer Ctr
Saint Louis Park, Minnesota, 55426
Cleveland CL N Coast Cancer Cr
Sandusky, Ohio, 44870
Willamette Valley Cancer Insitute and Research Center
Springfield, Oregon, 97477
Florida Cancer Specialists; Saint Petersburg
St. Petersburg, Florida, 33719
Northwest Medical Specialties
Tacoma, Washington, 98405
Arizona Oncology
Tucson, Arizona, 85704
Carle Cancer Center
Urbana, Illinois, 61801
Wenatchee Valley Hospital & Clinics
Wenatchee, Washington, 98801
Virginia Cancer Specialists - Winchester
Winchester, Virginia, 22601
Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates
Winston-Salem, North Carolina, 27103
Minnesota Oncology Hematology Woodbury
Woodbury, Minnesota, 55125
Italy31 sites
Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia
Alessandria, Piedmont, 15121
Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica
Bari, Apulia, 70124
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
Bologna, Emilia-Romagna, 40138
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
Brescia, Lombardy, 25123
Azienda Ospedaliero Univ
Catania, Sicily, 95124
Azienda Ospedaliera Univ
Florence, Tuscany, 50141
A.O. Universitaria S. Martino Di Genova; Ematologia 1
Genoa, Liguria, 16132
Ospedali Riuniti del Canavese
Ivrea, Piedmont, 10015
Az. Osp. Papardo; Struttura Complessa Di Ematologia
Messina, Sicily, 98165
Hospital San Raffaele
Milan, Lombardy, 20132
Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico
Milan, Lombardy, 20133
Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia
Milan, Lombardy, 20141
Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica
Naples, Campania, 80131
Nuovo Policlinico, Ii Facolta; Divisione Di Ematologia
Naples, Campania, 80131
Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad
Novara, Piedmont, 28100
Az. Osp. S. Luigi Gonzaga; S.C.D.U. Medicina Interna Ii
Orbassano, Piedmont, 10043
Ospedale "A.Tortora" - Ematologia; Dipartimento Di Ematologia
Pagani (Sa), Campania, 84016
Irccs Policlinico San Matteo; Divisione Di Ematologia
Pavia, Lombardy, 27100
Ospedale Santa Chiara; Unita Operativa Di Ematologia
Pisa, Tuscany, 56100
Ospedale Riuniti; Divisione Di Ematologia
Reggio Calabria, Calabria, 89100
AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia
Reggio Emilia, Emilia-Romagna, 42100
Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
Rome, Lazio, 00161
IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo
San Giovanni Rotondo, Apulia, 71013
Az. Osp. S. Maria; Dept. Di Oncologia Medica
Terni, Umbria, 05100
Ospedale Ca Foncello; Ematologia
Treviso, Veneto, 31100
Az. Osp. C. Panico; Rep. Ematologia E Trapianto
Tricase - LE, Apulia, 73039
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
Turin, Piedmont, 10126
A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia
Turin, Piedmont, 10126
A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica
Udine, Friuli Venezia Giulia, 33100
Uni Di Verona Policlinico G.B. Rossi; Divisione E Cattedra Di Ematologia
Verona, Veneto, 37130
Ospedale Di Vicenza; Nefrologia, Ematologia
Vicenza, Veneto, 36100
China28 sites
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, 100021
Peking University First Hospital
Beijing, 100034
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing, 100071
Beijing Cancer Hospital
Beijing, 100142
Beijing Hospital of Ministry of Health; Hematology
Beijing, 100730
General Hospital of Chinese PLA; Department of Hematology
Beijing, 100853
the First Hospital of Jilin University
Changchun, 130021
Hu Nan Provincial Cancer Hospital
Changsha, 410006
Fujian Medical University Union Hospital
Fujian, 350001
Fujian Cancer Hospital
Fuzhou, 350014
Sun Yet-sen University Cancer Center
Guangzhou, 510060
Guangdong General Hospital
Guangzhou, 510080
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, 310003
Harbin Medical University Cancer Hospital
Harbin, 150081
The Second Affiliated Hospital to Nanchang University
Nanchang, 330006
Jiangsu Cancer Hospital
Nanjing, 210009
Jiangsu Province Hospital
Nanjing, 210036
The First Affiliate Hospital of Guangxi Medical University
Nanning, 530021
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, 200025
Fudan University Shanghai Cancer Center
Shanghai, 200032
Changhai Hospital of Shanghai
Shanghai, 200433
First Hospital of China Medical University
Shenyang, 110001
The Second Affiliated Hospital of Soochow University
Suzhou, 215004
First Affiliated Hospital of Soochow University
Suzhou, 215006
Tianjin Cancer Hospital
Tianjin, 300060
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, 430022
Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center
Wuhan, 430023
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
Xi'an, 710038
Japan21 sites
Nagoya Daini Red Cross Hospital; Hematology & Oncology
Aichi, 466-8650
Chiba University Hospital; Hematology
Chiba, 260-8670
Kyushu University Hospital; Hematology, Oncology & Cardiovascular medicine
Fukuoka, 812-8582
Kurume University Hospital; Hematology and Oncology
Fukuoka, 830-0011
Gifu University Hospital; First Department of Internal Medicine
Gifu, 501-1194
Hokkaido University Hospital; Hematology
Hokkaido, 060-8648
Kobe City Medical Center General Hospital; Hematology
Hyōgo, 650-0047
Yokohama City University Hospital; Hematology, Rheumatology, Infectious Disease
Kanagawa, 236-0004
Kyoto University Hospital; Department of Hematology/Oncology
Kyoto, 606-8507
Niigata Cancer Center Hospital; Internal Medicine
Niigata, 951-8566
Iwate Medical University Hospital;Hematology and Oncology
Numakunai, 020-8505
Kurashiki Central Hospital; Hematology
Okayama, 710-8602
Osaka City University Hospital; Hematology
Osaka, 545-8586
Osaka University Hospital; Hematology and Oncology
Osaka, 565-0871
Kindai University Hospital; Hematology and Rheumatology
Osaka, 589-8511
Shimane University Hospital;Hematology
Shimane, 693-8501
Jichi Medical University Hospital; Hematology
Tochigi, 329-0498
National Cancer Center Hospital; Hematology
Tokyo, 104-0045
Toranomon Hospital; Hematology
Tokyo, 105-8470
Nippon Medical School Hospital; Hematology
Tokyo, 113-8603
The Cancer Institute Hospital of JFCR; Hematology Oncology
Tokyo, 135-8550
Canada15 sites
Tom Baker Cancer Centre; Dept of Medicine
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Queen Elizabeth II Health Sciences Centre; Oncology
Halifax, Nova Scotia, B3H 2Y9
Hopital Maisonneuve- Rosemont; Oncology
Montreal, Quebec, H1T 2M4
Chum Hopital Notre Dame; Centre D'Oncologie
Montreal, Quebec, H2L 4M1
Mcgill University - Royal Victoria Hospital; Oncology
Montreal, Quebec, H3A 1A1
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
Montreal, Quebec, H3T 1E2
Ottawa General Hospital
Ottawa, Ontario, K1H 8L6
Hopital de L'Enfant-Jesus; Hematology
Québec, Quebec, G1J 1Z4
Centre de sante et de services sociaux Rimouski Neigette
Rimouski, Quebec, G5L 5T1
Saskatoon Cancer Centre; Uni of Saskatoon Campus
Saskatoon, Saskatchewan, S7N 4H4
North York General Hospital
Toronto, Ontario, M2J 1V1
Humber River Hospital
Toronto, Ontario, M3M 0B2
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
Toronto, Ontario, M5G 2M9
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
Spain10 sites
Hospital del Mar; Servicio de Hematologia
Barcelona, 08003
Hospital Universitari Vall d'Hebron; Servicio de Hematologia
Barcelona, 08035
Hospital Clínic i Provincial; Servicio de Hematología y Oncología
Barcelona, 08036
Hospital Duran i Reynals; Servicio de Hematologia
Barcelona, 08907
Hospital Ramon y Cajal; Servicio de Hematologia
Madrid, 28034
Hospital de Navarra, Servicio de Hematología
Pamplona, Navarre, 31008
Complejo Hospitalario de Pontevedra; Servicio de Oncologia
Pontevedra, 36002
Hospital Universitari Sant Joan de Reus; Servicio de Oncologia
Reus, Tarragona, 43204
Hospital Universitario Virgen Macarena; Servicio de Oncologia
Seville, 41009
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
Toledo, 45004
Germany7 sites
Uniklinik RWTH Aachen; Klinik IV; Klinik Hämatologie, Onkologie, Hämostaseologie und Stammz
Aachen, 52074
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, 10707
Universitätsklinikum "Carl Gustav Carus"; Medizinische Klinik und Poliklinik I
Dresden, 01307
Friedrich-Alexander-Universität Erlangen-Nürnberg; Medizinische Klinik V
Erlangen, 91054
Klinik der Justus-Liebig-Universität; Innere Medizin
Giessen, 35392
Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V
Heidelberg, 69120
Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie
Würzburg, 97080
Hungary7 sites
Semmelweis University, First Dept of Medicine
Budapest, 1083
National Institute of Oncology, A Dept of Internal Medicine
Budapest, 1122
University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B
Debrecen, 4032
Petz Aladar Megyei Korhaz; Hematologia
Győr, 9024
Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology
Kaposvár, 7400
University of Pecs, I st Dept of Internal Medicine
Pécs, 7624
University of Szeged, II Dept of Internal Medicine
Szeged, 6720
South Korea7 sites
National Cancer Center
Gyeonggi-do, 10408
Chonnam National University Hwasun Hospital
Jeollanam-do, 58128
Seoul National University Hospital
Seoul, 03080
Asan Medical Center - Oncology
Seoul, 05505
Yonsei University Severance Hospital; Medical Oncology
Seoul, 120-752
St. Mary'S Hospital, the Catholic University School of Medicine; Internal Medicine
Seoul, 137-701
Samsung Medical Center
Seoul, 6351
Poland6 sites
Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny
Brzozów, 36-200
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
Gdansk, 80-952
Medical University of Lodz; Hematology
Lodz, 93-510
Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie
Lublin, 20-081
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego
Warsaw, 02-781
Medical Uni of Wroclaw; Hematology
Wroclaw, 50-367
Russia6 sites
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
Kazan', 420029
Blokhin Cancer Research Center; Clinical Oncology
Moscow, 115478
Regional Clinical Hospital N.A. Semashko; Hematology
Nizhny Novgorod, 603126
Penza Regional Oncology Dispensary
Penza, 440071
Republican Clinical Hospital n.a. Baranov; Haematology
Petrozavodsk, 185019
Research Inst. of Hematology & Blood Transfusion ; Hematology
Saint Petersburg, 191024
Thailand6 sites
King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine
Bangkok, 10330
National Cancer Inst.
Bangkok, 10400
Rajavithi Hospital; Medicine
Bangkok, 10400
Ramathibodi Hospital; Division of Hematology, Department of Medicine
Bangkok, 10400
Siriraj Hospital; Division of Hematology, Department of Medicine
Bangkok, 10700
Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine
Khon Kaen, 40002
Brazil5 sites
Centro de Pesquisas Oncologicas - CEPON
Florianópolis, Santa Catarina, 88034-000
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, 90470-340
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000
Instituto de Ensino e Pesquisa Sao Lucas - IEP
São Paulo, São Paulo, 01236-030
Hospital Santa Marcelina;Oncologia
São Paulo, São Paulo, 08270-070
South Africa5 sites
Constantiaberg Medical Clinic; Dept. of Haematology & Bone Marrow Translant
Cape Town, 7800
Mary Potter Oncology Centre
Groenkloof, 0181
Medical Oncology Centre of Rosebank; Oncology
Johannesburg, 2196
Wits Donald Gordon Clinical Trial Centre; Medical Oncology
Parktown, Johannesburg, 2193
Drs Thomson, Brittain an Partners Inc
Pretoria, 0044
United Kingdom5 sites
Aberdeen Royal Infirmary; Haematology - Ward 16
Aberdeen, AB25 2ZN
Birmingham Heartlands Hospital; Department of Haematology
Birmingham, B9 5SS
Addenbrookes Hospital; Haematology
Cambridge, CB2 0QQ
The HOPE Clinical Trials Unit
Leicester, LE1 5WW
New Cross Hospital; Dept. Of Haematology
Wolverhampton, WV10 0QP
Australia4 sites
Cairns Base Hospital; Cancer Care Centre
Cairns, Queensland, 4870
Frankston Hospital; Oncology/Haematology
Frankston, Victoria, 3199
Monash Medical Centre; Haematology
Melbourne, Victoria, 3168
Fiona Stanley Hospital
Murdoch, Western Australia, 6150
Mexico4 sites
Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre
Chihuahua City, 31000
Hospital Universitario Dr. Jose E. Gonzalez; Haematology
Monterrey, 64460
Oaxaca Site Management Organization
Oaxaca City, 68000
Centro de Estudios Clinicos de Queretaro, SC
Querétaro, 76000
Switzerland4 sites
Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie & Transfusionsmedizin
Aarau, 5001
Ospedale San Giovanni; Oncologia
Bellinzona, 6500
Kantonsspital Graubünden;Onkologie und Hämatologie
Chur, 7000
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
Zurich, 8091
Taiwan4 sites
Veterans General Hospital; Division of Oncology
Taipei, 00112
National Taiwan Universtiy Hospital; Division of Hematology
Taipei, 100
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
Taipei, 112
Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology
Taoyuan, 333
Argentina3 sites
Instituto Damic
Córdoba, X5003DCE
Sanatorio Britanico: Hematologia
Rosario, 2000
Sanatorio Parque de Rosario
Rosario, S2000DSV
Austria3 sites
Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie
Innsbruck, 6020
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Salzburg, 5020
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
Vienna, 1090
Colombia3 sites
Fundacion Cardioinfantil
Bogotá
Organizacion Sanitas Internacional
Bogotá
FOSCAL
Floridablanca
Czechia3 sites
Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
Brno, 625 00
Fn Hr. Kralove; IV. Interni Hematologicka Klinika
Hradec Králové, 500 05
Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
Prague, 128 08
Denmark3 sites
Aarhus Universitetshospital, Hæmatologisk Afdeling R
Aarhus, 8000
Rigshospitalet; Hæmatologisk Klinik
København Ø, 2100
Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium
Roskilde, 4000
Peru3 sites
Instituto Nacional de Enfermedades Neoplasicas
Lima, 15038
Instituto;Oncologico Miraflores
Lima, 18
Clinica de Especialidades Medicas
Lima, Lima 41
Hong Kong2 sites
Pamela Youde Nethersole Eastern Hospital; Department of Medicine
Hong Kong
Queen Mary Hospital; Dept of Medicine
Hong Kong
Serbia2 sites
Institute of Hematology
Belgrade, 11000
Clinical Center Vojvodine; Clinic for Hematology
Novi Sad, 21000
Slovakia1 site
National Oncology Inst. ; Dept. of Haematology
Bratislava, 833 10
About this study
Official title: A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.
- Conditions
- Diffuse Large B-Cell Lymphoma
- Being tested
- Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine
- Medical subject headings
- Lymphoma, Large B-Cell, Diffuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RituximabDrug
Also called MabThera, Rituxan
Rituximab at a dose of 375 mg/m^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
ObinutuzumabDrug
Also called GA101, RO5072759
Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
CyclophosphamideDrug
Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
DoxorubicinDrug
Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.
VincristineDrug
Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
PrednisoneDrug
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
| Study group | Role | What they receive |
|---|---|---|
| Rituximab+Chemotherapy | Active comparator | Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy. Receives: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone |
| Obinutuzumab+Chemotherapy | Experimental | Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy. Receives: Drug: Obinutuzumab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Median Time to Progression-Free Survival (PFS), Investigator-Assessed
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
Measured: Baseline up to approximately 6.5 years (up to 31 January 2018)
Secondary outcomes (15)
Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed
Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease [PD]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 cm or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants.
Measured: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Median Time to Overall Survival (OS)
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause.
Measured: Baseline up to approximately 6.5 years (up to 31 January 2018)
Overall Response Rate (ORR), Investigator-Assessed
Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.
Measured: Baseline up to approximately 6.5 years (up to 31 January 2018)
Overall Response Rate (ORR), IRC-Assessed
Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants.
Measured: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Complete Response (CR) at the End of Treatment, Investigator-Assessed
Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.
Measured: Baseline up to approximately 6.5 years (up to 31 January 2018)
Complete Response (CR) at the End of Treatment, IRC-Assessed
Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants.
Measured: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Median Time to Event-Free Survival (EFS), Investigator-Assessed
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT/MRI.
Measured: Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Median Time to Disease-Free Survival (DFS), Investigator-Assessed
Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm.
Measured: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Duration of Response (DOR), Investigator-Assessed
DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression >/= 50%. Progression/relapse: at least 50% increase in nodal lesions or >/=50% increase in any node > 1 cm or >/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.
Measured: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Time to Next Anti-Lymphoma Treatment (TTNALT)
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.
Measured: Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, approximately 6.5 years (31 January 2018)
Percentage of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Measured: Baseline up to approximately 6.5 years (up to 31 January 2018)
Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.
Measured: Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score
The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.
Measured: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores
The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.
Measured: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)
Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.
Measured: C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2011 (estimated)
- Study start26 Jul 2011
- Primary completion29 Apr 2016
- Study completion31 Jan 2018
Why it stopped: The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Diffuse Large B-Cell LymphomaStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,418 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Fondazione Italiana Linfomi - ETS
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01287741
- Sponsor's protocol ID
- BO21005
- Other IDs
- 2010-024194-39
- Status last verified
- Apr 2019
- First submitted
- 31 Jan 2011
- Last updated
- 12 Apr 2019
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Morschhauser F, Lenz G, Herrera AF, Flowers CR, Trneny M, Burke JM, Hou JZ, Staber PB, Hawkes EA, Izutsu K, Le Gouill S, Belada D, Tucci A, Yan M, Harris W, Lu K, Bolen CR, Hirata J, Lee C, Jiang Y, Jardin F, Hatzi K. Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL. Blood Neoplasia. 2026 Jul 2;3(4):100264. doi: 10.1016/j.bneo.2026.100264. eCollection 2026 Nov.
PubMed 42699559Torkaman M, Jemaa S, Fredrickson J, Fernandez Coimbra A, De Crespigny A, Carano RAD. Comparative analysis of intestinal tumor segmentation in PET CT scans using organ based and whole body deep learning. BMC Med Imaging. 2025 Feb 17;25(1):52. doi: 10.1186/s12880-025-01587-3.
PubMed 39962481Jemaa S, Ounadjela S, Wang X, El-Galaly TC, Kostakoglu L, Knapp A, Ku G, Musick L, Sahin D, Wei MC, Yin S, Bengtsson T, De Crespigny A, Carano RAD. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography. J Clin Oncol. 2024 Sep 1;42(25):2966-2977. doi: 10.1200/JCO.23.01978. Epub 2024 Jun 6.
PubMed 38843483Yan JT, Bel C, Trask PC, Lo E. Are changes in patient-reported outcomes prognostic for diffuse large B-Cell lymphoma survival? Results from the GOYA trial. J Patient Rep Outcomes. 2024 Mar 18;8(1):31. doi: 10.1186/s41687-024-00708-w.
PubMed 38498084Ho RS, Launonen A. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study. J Med Econ. 2023 Jan-Dec;26(1):1178-1189. doi: 10.1080/13696998.2023.2259107. Epub 2023 Sep 13.
PubMed 37702406Jemaa S, Paulson JN, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano RAD, El-Galaly TC, Nielsen TG, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging. 2022 Aug 12;22(1):39. doi: 10.1186/s40644-022-00476-0.
PubMed 35962459Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trneny M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg MS. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Adv. 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770.
PubMed 34323958Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trneny M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcgamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985.
PubMed 34323957Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trneny M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690.
PubMed 33651099Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, Paulson JN, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard MZ. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica. 2020 Sep 1;105(9):2298-2307. doi: 10.3324/haematol.2019.227892.
PubMed 33054054Sehn LH, Martelli M, Trneny M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020 Jun 6;13(1):71. doi: 10.1186/s13045-020-00900-7.
PubMed 32505213Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.
PubMed 31053601McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602.
PubMed 30770362Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.
PubMed 30617197Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.
PubMed 30341058
Study at a glance
From the registry record, last updated by the sponsor on 12 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- ClinicalTrials.gov ID
- NCT01287741
- Acronym / sponsor ID
- BO21005
- Conditions
- Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.
- Enrolment
- 1,418 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Collaborators
- Fondazione Italiana Linfomi - ETS
- Study start
- 26 Jul 2011 (actual)
- Primary completion
- 29 Apr 2016 (actual)
- Study completion
- 31 Jan 2018 (actual)
- First posted
- 1 Feb 2011 (estimated)
- Results
- Posted 17 Aug 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rituximab+Chemotherapy | Active comparator | Drug: Rituximab, Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Vincristine, Drug: PrednisoneParticipants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy. |
| Obinutuzumab+Chemotherapy | Experimental | Drug: Obinutuzumab, Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Vincristine, Drug: PrednisoneParticipants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Previously untreated CD20-positive DLBCL
- At least 1 bi-dimensionally measurable lesion (greater than [>]1.5 centimeters [cm] in its largest dimension on the computed tomography [CT] scan)
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- Adequate hematological function
- Low-intermediate, high-intermediate or high-risk International Prognostic Index (IPI) score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky disease, defined as one lesion greater than equal to (>/=) 7.5 cm)
Key exclusion criteria (8 listed)
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products or to any component of CHOP or obinutuzumab
- Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
- Participants with transformed lymphoma and participants with follicular lymphoma IIIB
- Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation
- Prior treatment with cytotoxic drugs or rituximab for another condition (for example, rheumatoid arthritis) or prior use of an anti-CD20 antibody
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RituximabAlso: MabThera, RituxanRituximab at a dose of 375 mg/m^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles. | Drug | Rituximab+Chemotherapy |
| ObinutuzumabAlso: GA101, RO5072759Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15. | Drug | Obinutuzumab+Chemotherapy |
| CyclophosphamideCyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| DoxorubicinDoxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| VincristineVincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| PrednisonePrednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
Primary outcome
Median Time to Progression-Free Survival (PFS), Investigator-Assessed
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
15 secondary outcomes
Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed
Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Median Time to Overall Survival (OS)
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Overall Response Rate (ORR), Investigator-Assessed
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Overall Response Rate (ORR), IRC-Assessed
Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Complete Response (CR) at the End of Treatment, Investigator-Assessed
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Complete Response (CR) at the End of Treatment, IRC-Assessed
Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Median Time to Event-Free Survival (EFS), Investigator-Assessed
Time frame: Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Median Time to Disease-Free Survival (DFS), Investigator-Assessed
Time frame: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Duration of Response (DOR), Investigator-Assessed
Time frame: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Time to Next Anti-Lymphoma Treatment (TTNALT)
Time frame: Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, approximately 6.5 years (31 January 2018)
Percentage of Participants With Adverse Events (AEs)
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
Time frame: Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score
Time frame: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores
Time frame: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)
Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Time frame: C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Apr 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42699559Morschhauser F, Lenz G, Herrera AF, Flowers CR, Trneny M, Burke JM, Hou JZ, Staber PB, Hawkes EA, Izutsu K, Le Gouill S, Belada D, Tucci A, Yan M, Harris W, Lu K, Bolen CR, Hirata J, Lee C, Jiang Y, Jardin F, Hatzi K. Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL. Blood Neoplasia. 2026 Jul 2;3(4):100264. doi: 10.1016/j.bneo.2026.100264. eCollection 2026 Nov.
- Derived from this study: PubMed 39962481Torkaman M, Jemaa S, Fredrickson J, Fernandez Coimbra A, De Crespigny A, Carano RAD. Comparative analysis of intestinal tumor segmentation in PET CT scans using organ based and whole body deep learning. BMC Med Imaging. 2025 Feb 17;25(1):52. doi: 10.1186/s12880-025-01587-3.
- Derived from this study: PubMed 38843483Jemaa S, Ounadjela S, Wang X, El-Galaly TC, Kostakoglu L, Knapp A, Ku G, Musick L, Sahin D, Wei MC, Yin S, Bengtsson T, De Crespigny A, Carano RAD. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography. J Clin Oncol. 2024 Sep 1;42(25):2966-2977. doi: 10.1200/JCO.23.01978. Epub 2024 Jun 6.
- Derived from this study: PubMed 38498084Yan JT, Bel C, Trask PC, Lo E. Are changes in patient-reported outcomes prognostic for diffuse large B-Cell lymphoma survival? Results from the GOYA trial. J Patient Rep Outcomes. 2024 Mar 18;8(1):31. doi: 10.1186/s41687-024-00708-w.
- Derived from this study: PubMed 37702406Ho RS, Launonen A. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study. J Med Econ. 2023 Jan-Dec;26(1):1178-1189. doi: 10.1080/13696998.2023.2259107. Epub 2023 Sep 13.
- Derived from this study: PubMed 35962459Jemaa S, Paulson JN, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano RAD, El-Galaly TC, Nielsen TG, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging. 2022 Aug 12;22(1):39. doi: 10.1186/s40644-022-00476-0.
- Derived from this study: PubMed 34323958Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trneny M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg MS. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Adv. 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770.
- Derived from this study: PubMed 34323957Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trneny M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcgamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985.
- Derived from this study: PubMed 33651099Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trneny M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690.
- Derived from this study: PubMed 33054054Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, Paulson JN, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard MZ. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica. 2020 Sep 1;105(9):2298-2307. doi: 10.3324/haematol.2019.227892.
- Derived from this study: PubMed 32505213Sehn LH, Martelli M, Trneny M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020 Jun 6;13(1):71. doi: 10.1186/s13045-020-00900-7.
- Derived from this study: PubMed 31053601Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.
Related trials for Diffuse Large B-Cell Lymphoma
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Not yet recruitingPhase 2
The CARDIOPROTECT Trial
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
Not yet recruitingPhase 2
QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study
Plasmablastic Lymphoma
RecruitingPhase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
235 sites in 29 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Rituximab, Obinutuzumab and Cyclophosphamide in people with Diffuse Large B-Cell Lymphoma, run by Hoffmann-La Roche at 235 sites in 29 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 12 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 235 sites in United States, Italy, China, Japan, Canada and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Aug 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Median Time to Progression-Free Survival (PFS), Investigator-Assessed (time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01287741, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2019.